Long-term use of standardised ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): A randomised placebo-controlled trial

The Lancet Neurology

Volumn 11, Issue 10, 2012, Pages 851-859

  Vellas, Bruno ^a,b,c   Coley, Nicola ^a,b,c   Ousset, Pierre Jean ^a,b,c   Berrut, Gilles ^d   Dartigues, Jean François ^a   Dubois, Bruno ^e   Grandjean, Hélène ^a   Pasquier, Florence ^f   Piette, François ^g   Robert, Philippe ^h   Touchon, Jacques ⁱ   Garnier, Philippe ^j   Mathiex Fortunet, Hélène ^j   Andrieu, Sandrine ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

^c TOULOUSE UNIVERSITY HOSPITAL   (France)

^d NANTES UNIVERSITY HOSPITAL   (France)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^f UNIV LILLE   (France)

^g HÔPITAL CHARLES FOIX   (France)

^h UNIVERSITY HOSPITAL OF NICE   (France)

ⁱ MONTPELLIER UNIVERSITY HOSPITAL   (France)

^j IPSEN   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GINKGO BILOBA EXTRACT; PLACEBO;

AGED; ALZHEIMER DISEASE; ANGINA PECTORIS; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CONTROLLED STUDY; DEATH; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; FRANCE; GASTROINTESTINAL SYMPTOM; HEART FAILURE; HEART INFARCTION; HUMAN; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MEMORY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; TREATMENT OUTCOME; VASCULAR DISEASE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MEMORY DISORDERS; PHYTOTHERAPY; PLANT EXTRACTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84866445630     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(12)70206-5     Document Type: Article

References (48)

1. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 2007, 3:186-191.
2. Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005, 366:2112-2117. the Alzheimer's Disease International.
3. Brookmeyer R, Gray S, Kawas C Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998, 88:1337-1342.
4. Wimo A, Winblad B, Jönsson L The worldwide societal costs of dementia: estimates for 2009. Alzheimers Dement 2010, 6:98-103.
5. Changing the trajectory of Alzheimer's disease: a national imperative Alzheimer's Association, (accessed Aug 1, 2011). http://www.alz.org/documents_custom/trajectory.pdf.
6. DeKosky ST, Williamson JD, Fitzpatrick AL, et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA 2008, 300:2253-2262. the Ginkgo Evaluation of Memory (GEM) Study Investigators.
7. Lyketsos CG, Breitner JC, Green RC, et al. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology 2007, 68:1800-1808. the ADAPT Research Group.
8. Sano M, Jacobs D, Andrews H, et al. A multi-center, randomized, double blind placebo-controlled trial of estrogens to prevent Alzheimer's disease and loss of memory in women: design and baseline characteristics. Clin Trials 2008, 5:523-533.
9. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003, 289:2651-2662. the WHIMS Investigators.
10. Vellas B, Andrieu S, Sampaio C, Coley N, Wilcock G Endpoints for trials in Alzheimer's disease: a European task force consensus. Lancet Neurol 2008, 7:436-450. the European Task Force Group.
11. Coley N, Andrieu S, Gardette V, et al. Dementia prevention: methodological explanations for inconsistent results. Epidemiol Rev 2008, 30:35-66.
12. Petersen RC, Roberts RO, Knopman DS, et al. Mild cognitive impairment: ten years later. Arch Neurol 2009, 66:1447-1455.
13. Aisen PS, Cummings J, Schneider LS Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease. Cold Spring Harb Perspect Med 2012, 2:a006395.
14. Andrieu S, Gillette S, Amouyal K, et al. Association of Alzheimer's disease onset with ginkgo biloba and other symptomatic cognitive treatments in a population of women aged 75 years and older from the EPIDOS study. J Gerontol A Biol Sci Med Sci 2003, 58:372-377. the EPIDOS study.
15. Marcocci L, Maguire JJ, Droy-Lefaix MT, Packer L The nitric oxide-scavenging properties of Ginkgo biloba extract EGb 761. Biochem Biophys Res Commun 1994, 201:748-755.
16. Pietri S, Maurelli E, Drieu K, Culcasi M Cardioprotective and anti-oxidant effects of the terpenoid constituents of Ginkgo biloba extract (EGb 761). J Mol Cell Cardiol 1997, 29:733-742.
17. Luo Y, Smith JV, Paramasivam V, et al. Inhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761. Proc Natl Acad Sci USA 2002, 99:12197-12202.
18. Bent S, Goldberg H, Padula A, Avins AL Spontaneous bleeding associated with ginkgo biloba: a case report and systematic review of the literature: a case report and systematic review of the literature. J Gen Intern Med 2005, 20:657-661.
19. Dartigues JF, Fabrigoule C, Letenneur L, Amieva H, Thiessard F, Orgogozo JM Epidemiology of memory disorders. Therapie 1997, 52:503-506.
20. Jonker C, Geerlings MI, Schmand B Are memory complaints predictive for dementia? A review of clinical and population-based studies. Int J Geriatr Psychiatry 2000, 15:983-991.
21. Chételat G, Villemagne VL, Bourgeat P, et al. Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. Ann Neurol 2010, 67:317-324. the Australian Imaging Biomarkers and Lifestyle Research Group.
22. Andrieu S, Ousset PJ, Coley N, Ouzid M, Mathiex-Fortunet H, Vellas B GuidAge study: a 5-year double blind, randomised trial of EGb 761 for the prevention of Alzheimer's disease in elderly subjects with memory complaints. I: rationale, design and baseline data. Curr Alzheimer Res 2008, 5:406-415. the GuidAge study GROUP.
23. Folstein MF, Folstein SE, McHugh PR "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975, 12:189-198.
24. Lipman T, Covi L Outpatient treatment of neurotic depression: medication and group psychotherapy. Evaluation of sychological therapies 1976, 181-202. Johns Hopkins University Press, Baltimore, MD. R. Spitzer, D. Klein (Eds.).
25. Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 1982-83, 17:37-49.
26. Grober E, Buschke H, Crystal H, Bang S, Dresner R Screening for dementia by memory testing. Neurology 1988, 38:900-903.
27. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL A new clinical scale for the staging of dementia. Br J Psychiatry 1982, 140:566-572.
28. Diagnostic and statistical manual of mental disorders 1994, APA, American Psychiatric Association, Washington, DC. 4th edn.
29. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
30. McNair D, Kahn R Self-assessment of cognitive deficits. Assessment in clinical psychopharmacology 1983, 137-143. Mark Powley, New Canaan, CT. T. Crook, A. Ferris, R. Baltus (Eds.).
31. Kanowski S, Herrmann WM, Stephan K, Wierich W, Hörr R Proof of efficacy of the ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. Pharmacopsychiatry 1996, 29:47-56.
32. Maurer K, Ihl R, Dierks T, Frölich L Clinical efficacy of Ginkgo biloba special extract EGb 761 in dementia of the Alzheimer type. J Psychiatr Res 1997, 31:645-655.
33. Reitan R Validity of the Trail Making Test as an indicator of brain damage. Percept Mot Skills 1958, 8:271-276.
34. Cardebat D, Doyon B, Puel M, Goulet P, Joanette Y Formal and semantic lexical evocation in normal subjects. Performance and dynamics of production as a function of sex, age and educational level. Acta Neurol Belg 1990, 90:207-217.
35. Lawton MP, Brody EM Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969, 9:179-186.
36. Kawas C, Gray S, Brookmeyer R, Fozard J, Zonderman A Age-specific incidence rates of Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Neurology 2000, 54:2072-2077.
37. Rothwell PM Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet 2005, 365:176-186.
38. Lind DY, Wei LJ The robust inference for the proportional hazards model. J Am Stat Assoc 1989, 84:1074-1078.
39. Snitz BE, O'Meara ES, Carlson MC, et al. Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial. JAMA 2009, 302:2663-2670. the Ginkgo Evaluation of Memory (GEM) Study Investigators.
40. Dodge HH, Zitzelberger T, Oken BS, Howieson D, Kaye J A randomized placebo-controlled trial of Ginkgo biloba for the prevention of cognitive decline. Neurology 2008, 70:1809-1817.
41. Breitner JC, Baker LD, Montine TJ, et al. Extended results of the Alzheimer's disease anti-inflammatory prevention trial. Alzheimers Dement 2011, 7:402-411. the ADAPT Research Group.
42. Jorm AF, Masaki KH, Davis DG, et al. Memory complaints in nondemented men predict future pathologic diagnosis of Alzheimer disease. Neurology 2004, 63:1960-1961.
43. Palmer K, Bäckman L, Winblad B, Fratiglioni L Detection of Alzheimer's disease and dementia in the preclinical phase: population based cohort study. BMJ 2003, 326:245.
44. Verdelho A, Madureira S, Moleiro C, et al. Self-perceived memory complaints predict progression to Alzheimer disease. The LADIS study. J Alzheimers Dis 2011, 27:491-498. the LADIS Study.
45. Green RC, DeKosky ST Primary prevention trials in Alzheimer disease. Neurology 2006, 67(suppl 3):S2-S5.
46. Dangour AD, Allen E, Richards M, Whitehouse P, Uauy R Design considerations in long-term intervention studies for the prevention of cognitive decline or dementia. Nutr Rev 2010, 68(suppl 1):S16-S21.
47. Letenneur L, Gilleron V, Commenges D, Helmer C, Orgogozo JM, Dartigues JF Are sex and educational level independent predictors of dementia and Alzheimer's disease? Incidence data from the PAQUID project. J Neurol Neurosurg Psychiatry 1999, 66:177-183.
48. Ferris SH, Aisen PS, Cummings J, et al. ADCS Prevention Instrument Project: overview and initial results. Alzheimer Dis Assoc Disord 2006, 20(suppl 3):S109-S123. the Alzheimer's Disease Cooperative Study Group.